Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc To Return Rights To Three Acura Pharmaceuticals, Inc.'s Products-Reuters


Friday, 27 Jul 2012 06:02pm EDT 

Reuters reported that Pfizer Inc will return three products it was developing using Acura Pharmaceuticals Inc's abuse resistant technology, Acura said on July 27, 2012. The license termination, which concerns three clinical stage products using Acura's Aversion technology, will be effective a year from Thursday, when Pfizer notified Acura. The Pfizer will retain rights to Oxecta and return all assets and regulatory and clinical responsibility related to the three drugs, MacKay Jimeson, a spokesman for Pfizer, told Reuters via email. Acura had received an aggregate of $78.5 million in payments from Pfizer as of March 31, under their 2007 license agreement. It was eligible to receive tiered royalties of 5% to 25% on combined annual net sales of all products marketed under the agreement. 

Company Quote

1.06
-0.028 -2.57%
11 Jul 2014